Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bimekizumab in palmoplantar pustulosis
CTR20253930Phase 3Active
- Sponsor
- UCB
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bimekizumab in Palmoplantar Pustular Psoriasis (PPPP), sponsored by UCB. Started Mar 2026; status: active.
02
Drugs
bimekizumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on CTR20253930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253930.